INmune Bio
INMB
48 hedge funds and large institutions have $25.8M invested in INmune Bio in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 3 closing their positions.
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
78% more capital invested
Capital invested by funds: $14.5M → $25.8M (+$11.3M)
76% more call options, than puts
Call options by funds: $645K | Put options by funds: $367K
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
30% more funds holding
Funds holding: 37 → 48 (+11)
0.88% more ownership
Funds ownership: 11.85% → 12.73% (+0.88%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$362K |
| 2 |
Citigroup
New York
|
+$301K |
| 3 |
LNWTC
Laird Norton Wetherby Trust Company
Seattle,
Washington
|
+$264K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$247K |
| 5 |
BlackRock
New York
|
+$210K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$782K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$366K |
| 3 |
FA
Fermata Advisors
Sonoma,
California
|
-$229K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$125K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$83.8K |
INMB Hedge Fund Activity: Q4 2023 in Review
48 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q4 2023, worth a combined $25.8M — up 78% from $14.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new INMB positions and 3 closed out — a net gain of 11 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $362K. The largest seller was Janney Montgomery Scott, cutting an estimated $782K.
- 48 institutional investors held INmune Bio (INMB) as of Q4 2023, up from 37 in Q3 2023.
- Funds reported $25.8M of INmune Bio stock for Q4 2023, up 78% quarter-over-quarter.
- 14 funds opened new INmune Bio positions in Q4 2023 and 3 closed out, a net change of +11 holders.
- The largest INmune Bio buyer in Q4 2023 was Jane Street, an estimated $362K added.
- The largest INmune Bio seller in Q4 2023 was Janney Montgomery Scott, an estimated $782K sold.
Based on aggregated 13F filings for Q4 2023.